Key Takeaways
- Medtronic is expected to continue its strong performance in 2026, despite some challenges in the past year.
- The company’s decision to separate its diabetes business will simplify its operations and unlock more profitable growth opportunities.
- Medtronic’s entry into the robotic-assisted surgery market with the Hugo system represents a long-term growth driver.
- The company’s dividend streak, with 48 consecutive years of increases, makes it an attractive option for income-seeking investors.
Introduction to Medtronic’s Strong Performance
Medtronic, a healthcare giant, is coming off a strong year, with a solid performance in 2025 despite some threats to its business, including the impact of tariffs on its operations. As 2026 begins, the company is expected to continue its strong performance, making it an attractive option for investors, particularly those seeking long-term income. There are several reasons why Medtronic is a good investment opportunity, and this article will explore three of them in detail.
Simplification of Medtronic’s Business
One of the key reasons why Medtronic is expected to perform well is its decision to separate its diabetes business into a stand-alone, publicly traded entity. This transaction is expected to be complete by the end of 2026, and it will simplify Medtronic’s operations, allowing the company to focus on its more profitable business-to-business (B2B) operations. The diabetes care unit, which accounts for 8% of Medtronic’s revenue, generates significantly lower operating margins than the rest of the business, and its separation will unlock more profitable growth opportunities for the company. Additionally, Medtronic was struggling to keep pace with industry leaders in certain niches of the diabetes care market, and the separation will allow the company to focus on its core strengths.
New Growth Driver: Robotic-Assisted Surgery
Another reason why Medtronic is an attractive investment opportunity is its entry into the robotic-assisted surgery (RAS) market with the Hugo system. The company received regulatory clearance in the U.S. for the Hugo system last year, and while it may not boost Medtronic’s top-line growth in the short term, it represents an important long-term opportunity for the company. The RAS market is underpenetrated, with attractive long-term prospects, and Medtronic’s entry into this market will allow the company to capitalize on the growing demand for minimally invasive procedures. The Hugo system will eventually contribute meaningfully to Medtronic’s results, making it a significant growth driver for the company.
Medtronic’s Fantastic Dividend Streak
Medtronic is also an excellent stock for dividend-seeking investors, with a dividend streak of 48 consecutive years of increases. The company offers a forward yield of 3%, making it an attractive option for investors seeking regular income. Medtronic is on track to become a Dividend King, with at least 50 straight years of annual dividend increases, and it will continue to hike its payouts long after that. This makes Medtronic a reliable option for investors seeking long-term income, and its dividend streak is a key factor in its attractiveness as an investment opportunity.
Conclusion
In conclusion, Medtronic is a strong investment opportunity, with a simplified business, a new growth driver in the RAS market, and a fantastic dividend streak. The company’s decision to separate its diabetes business will unlock more profitable growth opportunities, while its entry into the RAS market will provide a long-term growth driver. Medtronic’s dividend streak, with 48 consecutive years of increases, makes it an attractive option for income-seeking investors. Overall, Medtronic is a solid choice for investors seeking long-term growth and income, and its strong performance in 2025 is expected to continue in 2026.